Mostrando 10 resultados de: 30
Filtros aplicados
Publisher
OMICS A Journal of Integrative Biology(5)
Drug Metabolism and Drug Interactions(4)
Pharmacogenomics Journal(3)
Drug Metabolism and Personalized Therapy(2)
Translational Psychiatry(2)
Área temáticas
Farmacología y terapéutica(21)
Enfermedades(11)
Fisiología humana(8)
Medicina y salud(8)
Bioquímica(6)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(30)
ODS 10: Reducción de las desigualdades(23)
ODS 17: Alianzas para lograr los objetivos(23)
ODS 9: Industria, innovación e infraestructura(7)
ODS 12: Producción y consumo responsables(3)
Origen
google(4)
High frequency of CYP2D6 ultrarapid metabolizers in Spain: Controversy about their misclassification in worldwide population studies
ArticleAbstract: A high frequency (7-10%) of CYP2D6 ultrarapid metabolizers estimated from the genotype (gUMs) has bePalabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Delgado A., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusHigh prevalence of CYP2D6 ultrarapid metabolizers in a mestizo Colombian population in relation to Hispanic mestizo populations
ArticleAbstract: Background: Interethnic differences in CYP2D6 allele frequency have been demonstrated across Latin-APalabras claves:COLOMBIA, CYP2D6, Hispanics, Mestizos, Ultrarapid metabolizersAutores:Adrián LLerena, Borbón-Orejuela A., de Andrés F., Dorado P., P Sarmiento A.Fuentes:scopusHigh-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients
ArticleAbstract: Background: Aripiprazole (ARI) is an antipsychotic drug that is metabolized to dehydroaripiprazole (Palabras claves:Aripiprazole, CYP2D6, Dehydroaripiprazole, High-performance liquid chromatography, Psychiatric patientsAutores:Adrián LLerena, de Andrés F., De la Rubia A., Dorado P., Gonz Ález A., Gonz Ález I., Naranjo M.E.G., Peñ As-Lledó E.Fuentes:scopusEvaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: The CEIBA cocktail
ReviewAbstract: Interindividual differences in response to drug treatments are mainly caused by differences in drugPalabras claves:Cocktail, Cytochrome P450 (CYP), Genotype, Hispanics, PhenotypeAutores:Adrián LLerena, Alonso-Vilatela E., Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Fiedler J., Francisco J.López Hernández, Galaviz-Hernandez C., Garza-Ocañas L., González-Vacarezza N., Grazina M., Herrera L., Jiménez-Arce G., LARES, Lazalde-Ramos B.P., Leonardo J. Beltrán, López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Natalia Heras, Ochoa-Morales A., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rojas-Martinez A., Rojas-Ponce R., Sarmiento A.P., Sosa-Macías M.G., Tarazona-Santos E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusFrequency of CYP2C9 (*2, *3 and IVS8-109A>T) allelic variants, and their clinical implications, among mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin
ArticleAbstract: The majority of Mexican patients with diabetes mellitus type 2 (DMT2) (67.9-85.0%) are prescribed suPalabras claves:Cytochrome P450 2C9, DIABÉTES, Glibenclamide, Glycated hemoglobin A1c, MetforminAutores:Adrián LLerena, Castillo-Nájera F., Cuautle-Rodríguez P., de Andrés F., Molina-Guarneros J.A., Rodríguez-Rivera N.S.Fuentes:scopusGenomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
ArticleAbstract: We present the distribution of CYP2D6, CYP2C9, and CYP2C19 variants and predicted phenotypes in 33 nPalabras claves:Autores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Michelin L.A., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusEffects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations
ArticleAbstract: In a one-way cross-over study, we investigated the effect of Khat, a natural amphetamine-like psychoPalabras claves:Autores:Adrián LLerena, Aklillu E., Bedada W., de Andrés F., Engidawork E., Hussein J.Fuentes:scopusDevelopment of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes
ArticleAbstract: Background: Losartan is metabolized to losartan carboxylic acid (E-3174) by the polymorphic cytochroPalabras claves:CYP2C9*Hispanics, LOSARTÁN, pharmacogenetics, PhenotypeAutores:Adrián LLerena, de Andrés F., Dorado P., Machín E., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCurrent insights into interethnic variability in testicular cancers: Population pharmacogenetics, clinical trials, genetic basis of chemotherapyinduced toxicities and molecular signal transduction
ReviewAbstract: Testicular cancer is an aggressive malignancy with a rising incidence rate across the globe. TesticuPalabras claves:clinical trials, ethnicity, Molecular aspects, pharmacogenetics, Pharmacogenomics, population pharmacogenetics, Precision Medicine, signal transduction, Testicular cancer, Testicular seminoma, Toxicity, Variant polymorphismAutores:Adrián LLerena, de Andrés F., Kothari R., Mishra A., Nair S., Vasistha A.Fuentes:scopusCurrent perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction
ArticleAbstract: Multiple myeloma (MM) is an aggressive cancer characterised by malignancy of the plasma cells and aPalabras claves:Cáncer, Drug resistance, Interethnic variability, Molecular aspects, Multiple myeloma, population pharmacogenetics, Precision Medicine, signal transductionAutores:Adrián LLerena, Bakhai V., de Andrés F., Gandhi M., Mishra A., Nair S., Sharma R., Trivedi J.Fuentes:scopus